{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 470610217
| image =
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu/o
| target = [[TNFRSF10B]] (TRAIL-R2)
<!-- Clinical data -->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 918127-53-4
| ATC_prefix = none
| ATC_suffix =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| C=6406 | H=9924 | N=1716 | O=2012 | S=46
| molecular_weight = 144.6 kg/mol
}}
'''Tigatuzumab''' ('''CS-1008''') is a [[monoclonal antibodies|monoclonal antibody]]<ref>[http://www.who.int/medicines/services/inn/RL60prepublication.pdf WHO Drug Information]</ref> for the treatment of cancer. {{as of|2009|10}}, a [[clinical trial]] for the treatment of [[pancreatic cancer]] has been completed,<ref>[[National Cancer Institute|NCI]]: [http://www.cancernet.gov/ncicancerbulletin/042109/page3 Combination Therapy Targets Pancreatic Cancer Stem Cells]</ref> Phase II trials for [[colorectal cancer]]<ref>NCI: [http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=654374&version=HealthProfessional&protocolsearchid=6875774 CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin]</ref> and non-small cell [[lung cancer]]<ref>NCI: [http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=657101&version=HealthProfessional&protocolsearchid=6875774 CS-1008 With Carboplatin/Paclitaxel in Chemotherapy na√Øve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)]</ref> are running, and a study for [[ovarian cancer]] has been approved.<ref>NCI: [http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=650804&version=HealthProfessional&protocolsearchid=6875774 Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer]</ref>

The drug targets [[TNFRSF10B|member 10b of the tumor necrosis factor receptor superfamily]] (TNFRSF10B, better known as death receptor 5 or trail receptor 2), a protein overexpressed in many kinds of tumour.<ref>NCI: [http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=489323 CS-1008]</ref>

== References ==
<references/>

{{Monoclonals for tumors}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}